Summary
Symptoms of cardiotoxicity resulting from cancer therapy, sometimes manifesting years or even decades later, are a problem for survivors. In a special session on cardio-oncology, expert consensus recommendations from the European Association of Cardiovascular Imaging on best practices for detecting signs of cardiotoxicity in cancer survivors were reviewed.
- multimodality imaging
- cardiotoxicity
- radiotherapy
- chemotherapy
- radiation-induced heart disease
- cardiovascular risk
- trastuzumab
- anthracycline
- monoclonal antibody
- tyrosine kinase inhibitor
- © 2014 SAGE Publications